Latest News
Here you can find all the latest news from the MRC CTU at UCL.
First National Meeting of the ACORD Collaboration
We hosted a successful first meeting of the ACORD Collaboration on Wednesday 8th June 2022.
Weekly chemotherapy no better than three-weekly chemotherapy for people with ovarian cancer
Having chemotherapy every week does not improve survival for people with ovarian cancer compared to having it once every three weeks.
Adding radiotherapy can benefit some patients whose prostate cancer has spread
Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer.
A meta-analysis study shows which patients with advanced prostate cancer live longer with chemotherapy
Docetaxel chemotherapy is substantially more effective for some patients with advanced prostate cancer than others.
Abiraterone, combined with standard therapy, helps men with metastatic prostate cancer to live longer
Adding the drug abiraterone to standard hormone therapy improves the survival of men with prostate cancer that has spread to other parts of the body.